The Cancer History Project’s mission includes publishing books that tell the story of oncology and the shaping of its culture.
Susan Love, breast oncologist, founder of the breast cancer advocacy movement, and chief visionary officer of the Dr. Susan Love Foundation for Breast Cancer Research, died July 2.
Radiation oncologist William Blackstock died from his long battle with prostate cancer June 18. He was 60.
Bill Nelson, director of Johns Hopkins Kimmel Cancer Center, is conducting a series of interviews commemorating the cancer center’s 50th anniversary.
Johns Hopkins Medicine received a $35 million gift from researcher, philanthropist, and race car driver Theodore Giovanis. Scientists will use the gift to study how cancer metastasizes through the body.
SpaceMarkers, a machine learning software developed by researchers at the Johns Hopkins Convergence Institute and the Johns Hopkins Kimmel Cancer Center, can identify molecular interactions among distinct types of cells in and around a tumor, according to a study published in Cell Systems.
In a phase II, single-arm study published in Clinical Cancer Research, a journal of the American Association for Cancer Research, patients with resectable non-small cell lung cancer who were treated with neoadjuvant nivolumab had improved five-year recurrence-free and overall survival rates compared with historical outcomes.
Three-year (36.5 months minimum; 44.0 months median) follow-up results from the phase III CheckMate -9ER trial demonstrated sustained survival and response rate benefits with the combination of Opdivo (nivolumab) and Cabometyx (cabozantinib) versus sunitinib in the first-line treatment of advanced renal cell carcinoma, according to Bristol Myers Squibb and Exelixis Inc.
Investigators at the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel Institute for Cancer Immunotherapy have found that a subset of mutations within the overall tumor mutation burden, termed “persistent mutations,” are less likely to be edited out as cancer evolves, rendering tumors continuously visible to the immune system and predisposing them to respond to immunotherapy.
In a study from the Johns Hopkins Kimmel Cancer Center, researchers described a novel mechanism of tumor formation in kidney cancers driven by overexpression of the mechanistic target of rapamycin complex 1 signaling pathway with loss of the tuberous sclerosis complex tumor suppressor gene.
